Are the side effects of Ixazomib severe?

Ixazomib is classified as an antineoplastic agent (anticancer drug). Its mechanism of action involves interfering with the growth of cancer cells and ultimately enabling the body to eliminate them.

Are the side effects of Ixazomib severe?

Some side effects may occur but usually do not require medical intervention. These side effects may disappear on their own during treatment as the body gradually adapts to the medication. In addition, your healthcare provider can advise you on ways to prevent or alleviate certain side effects. If any of the following side effects persist, cause discomfort, or if you have any questions about them, consult your healthcare provider.

Some patients may also experience other side effects not listed herein. If you notice any other effects, consult your healthcare provider.

During medication administration, some relatively common side effects may include back pain, body aches, as well as visual changes such as blurred vision. Ocular discomfort may occur, for example, a burning sensation, dryness or itching, which may also be accompanied by increased secretions or abnormal tearing, and even redness, pain or swelling of the eyes, eyelids or their inner side.

Some people may feel ear fullness or develop hoarseness, accompanied by respiratory symptoms such as nasal congestion and sneezing. In addition, digestive system reactions such as difficulty in defecation may also occur.

Precautions for Contraception

1. Female patients should be informed of the potential risks of the drug to the fetus and should avoid pregnancy during treatment.

2. Male and female patients of childbearing potential must use effective contraceptive measures during treatment and for 90 days after the last dose.

3. Dexamethasone is known to have weak to moderate inducing effects on CYP3A4 as well as other enzymes and transporters. Since this product is administered in combination with dexamethasone, the risk of reduced contraceptive efficacy should be taken into consideration. It is recommended that women using hormonal contraceptives adopt a barrier contraceptive method at the same time.

Precautions for Lactation

1. Currently, there are no data available on the presence of this product in human milk. The effects of the drug on breastfed infants and on milk secretion are unclear. 

2. Due to the unknown risk of serious adverse reactions that this product may cause to breastfed infants, it is recommended that lactating women do not breastfeed during treatment and for 90 days after the last dose.